Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.1%
    Check dated 2026-03-12T04:29:36.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is added, replacing earlier revisions. The funding-lapse notice and Revision v3.4.1 have been removed.
    Difference
    0.4%
    Check dated 2026-02-11T17:09:18.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added a site-wide notice about possible delays due to funding, and updated the page revision to v3.4.1. The previous revision was v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T10:48:13.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    UI updates include a new 'Show glossary' option and minor text changes such as capitalization of labels and an updated revision/version to v3.4.0. No substantive study content, outcomes, or eligibility details were altered.
    Difference
    0.2%
    Check dated 2026-01-28T06:38:50.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page shows an administrative revision label: v3.3.4, replacing the previous v3.3.3. No core study content, eligibility criteria, locations, or outcomes were changed.
    Difference
    0.1%
    Check dated 2026-01-14T03:27:18.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added a Locations section listing North Carolina (Duke University Medical Center, Durham) and South Carolina (Columbia and Lexington Medical Center) study sites, replacing the prior separate state location headings; removed the HHS Vulnerability Disclosure link in the footer as part of Revision: v3.3.3.
    Difference
    0.3%
    Check dated 2025-12-23T21:56:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.